http://www.dalton.com Learn about Dalton Pharma Services current news and events. Fri, 14 Oct 2011 17:36:32 GMT http://www.dalton.com/news_article_name/pharma_services_contract.aspx Dalton Pharma Services, today announced the Company is scheduled to present at the 10th Annual Contract Pharma, Contracting & Outsourcing Conference and Tabletop Exhibition on Sep 22nd, from 10 am to 4 pm. Thu, 22 Sep 2011 00:00:00 GMT http://www.dalton.com/news_article_name/chemoutsourcing.aspx Dalton Pharma Services today announced that the Company is scheduled to attend ChemOutsourcing, an annual pharmaceutical chemistry conference in Long Branch, New Jersey. Mon, 12 Sep 2011 00:00:00 GMT http://www.dalton.com/news_article_name/aseptic_fill_services.aspx Dalton Pharma Services announced that it has entered into a Aseptic Fill Manufacturing Services Agreement with Zafgen Inc. Mon, 16 May 2011 00:00:00 GMT http://www.dalton.com/news_article/38.aspx Dalton Pharma Services today announced the company has entered into an API Manufacturing & Aseptic Fill Services Agreement with Oncovir Inc. Thu, 03 Feb 2011 00:00:00 GMT http://www.dalton.com/news_article/39.aspx The Ontario Network of Excellence (ONE) is a collaborative network of regional innovation centres across Ontario, and is an important part of the aggressive innovation agenda to ensure that the Province will continue to flourish in the fiercely competitive global marketplace. Thu, 03 Feb 2011 00:00:00 GMT http://www.dalton.com/news_article_name/scar_tissue_reduction.aspx Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Clinical Manufacturing Services Agreement with AdeTherapeutics (ā day’ therapeutics), Inc., a specialty pharma company based in Saskatoon, Saskatchewan, focused on providing quality therapeutic options in inflammation and acute care medicine. Mon, 10 Jan 2011 00:00:00 GMT http://www.dalton.com/news_article_name/biotechnology.aspx Dalton Pharma Services Announces Bronze Sponsorship for the 2010 Healthcare & Biotechnology Venture Challenge. Thu, 25 Nov 2010 00:00:00 GMT http://www.dalton.com/news_article_name/contract_chemistry_services.aspx Dalton Pharma Services and Lonza jointly announce a co-operation created to provide clients with geographically diversified, fully integrated chemistry services from bench to commercial production of active pharmaceutical ingredients. Mon, 22 Nov 2010 00:00:00 GMT http://www.dalton.com/news_article_name/off_shore_pharma.aspx Upheaval in the pharmaceutical industry of off shoring pharma is causing a massive shift of R&D from North America to China and India. Thu, 07 Oct 2010 00:00:00 GMT http://www.dalton.com/news_article/1.aspx Dalton Announces Successful Completion of Health Canada Inspection and Compliance with European Directive for Manufacture and Testing of Drug Products Imported to the European Union. Mon, 01 Feb 2010 00:00:00 GMT http://www.dalton.com/news_article/2.aspx BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry have jointly announced a renewal of their exclusive worldwide collaboration and agreement to discover and develop new ophthalmology therapeutics. Thu, 29 Oct 2009 00:00:00 GMT http://www.dalton.com/news_article/3.aspx Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities. Mon, 21 Sep 2009 00:00:00 GMT http://www.dalton.com/news_article/4.aspx Dalton Pharma Services and ProCitius Research jointly announce a strategic alliance created to provide clients with contract chemistry services of exceptional value. Mon, 11 May 2009 00:00:00 GMT http://www.dalton.com/news_article/5.aspx BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics. Mon, 23 Mar 2009 00:00:00 GMT http://www.dalton.com/news_article/6.aspx Dalton Pharma Services announces the renewal of its Chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd. Under the agreement Dalton will continue to provide chemistry services in support of Boehringer's pharmaceutical development programs. Mon, 23 Feb 2009 00:00:00 GMT http://www.dalton.com/news_article/7.aspx The Myelin Repair Foundation and Dalton Pharma Services jointly announce a chemistry collaboration to develop new potential therapeutic compounds for myelin degradation disease states such as Multiple Sclerosis (MS). Wed, 22 Oct 2008 00:00:00 GMT http://www.dalton.com/news_article/8.aspx Dalton Pharma Services is pleased to announce the expansion of its Contract Analytical Services with the commissioning of two validated LC-MS/MS instruments which have been qualified for GMP testing of pharmaceutical products. Tue, 15 Jul 2008 00:00:00 GMT http://www.dalton.com/news_article/9.aspx Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider, and Thermo Fisher Scientific have entered into an agreement under which Dalton will use a proprietary Thermo Fisher manufacturing process to produce nucleic-acid biopolymers for pharmaceutical use. Tue, 06 May 2008 00:00:00 GMT http://www.dalton.com/news_article/10.aspx BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry, have jointly announced an exclusive worldwide collaboration and agreement to discover and develop new therapeutics for unmet needs in ophthalmology. Sat, 03 May 2008 00:00:00 GMT http://www.dalton.com/news_article/11.aspx Dalton Medicinal Chemistry Partners is utilizing their medicinal chemistry expertise to design and synthesize novel compounds against an antiviral target selected by Boehringer Ingelheim (Canada) Ltd. Wed, 23 Jan 2008 00:00:00 GMT http://www.dalton.com/news_article/12.aspx Canadian vaccine specialist ImmunoVaccine Technologies (IVT) has scored a multi-million dollar grant to go towards developing its potent immune enhancement systems. Tue, 22 Jan 2008 00:00:00 GMT http://www.dalton.com/news_article/13.aspx Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected RiboSwitch targets. BioRelix will advance these compounds using their cutting edge battery of biological assays and thorough knowledge of RiboSwitch drug discovery and development. Tue, 13 Nov 2007 00:00:00 GMT http://www.dalton.com/news_article/14.aspx Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved a targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd. The milestone achievement triggered payment of an undisclosed amount. Sat, 27 Oct 2007 00:00:00 GMT http://www.dalton.com/news_article/15.aspx Dalton enters into a long term Manufacturing Services Agreement with X-GEN Pharmaceuticals, Inc., a specialty pharma company based in Big Flats, New York, focused on providing quality therapeutic options in both specialized disease areas and broad range treatment choices. Thu, 14 Jun 2007 00:00:00 GMT http://www.dalton.com/news_article/16.aspx Dalton Medicinal Chemistry Partners will utilize their medicinal chemistry services expertise to design and synthesize novel compounds against a number of antiviral targets selected by Boehringer Ingelheim (Canada) Ltd. Wed, 23 May 2007 00:00:00 GMT http://www.dalton.com/news_article/17.aspx Affectis has contracted Dalton for the manufacturing of preclinical tox material with potential for cGMP production. Thu, 01 Mar 2007 00:00:00 GMT http://www.dalton.com/news_article/18.aspx A Positive rating from regulatory agency clears way for delivery of commercial products to clients of the Company’s Drug Manufacturing services. Fri, 26 Jan 2007 00:00:00 GMT http://www.dalton.com/news_article/19.aspx Dalton Pharma Services announces the formation of Dalton Medicinal Chemistry Partners, a joint venture with Dr. Judd Berman. The joint venture now offers expanded, mechanism based medicinal chemistry services to companies involved in drug discovery. Thu, 31 Aug 2006 00:00:00 GMT http://www.dalton.com/news_article/20.aspx Dalton Pharma Services, provider to leading pharmaceutical companies, today announced the completion of its state-of-art Oligonucleotide Production Suite. Wed, 12 Apr 2006 00:00:00 GMT http://www.dalton.com/news_article/21.aspx Dalton Chemical Laboratories Inc. is proud to announce that they will now be operating as Dalton Pharma Services. Thu, 31 Mar 2005 00:00:00 GMT http://www.dalton.com/news_article/22.aspx Dalton Chemical Laboratories, Inc., a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced it has completed Phase III of its facilities expansion. Mon, 25 Oct 2004 00:00:00 GMT http://www.dalton.com/news_article/23.aspx The Company's move of its entire manufacturing process for its proprietary products NeoVisc(R) and Uracyst(R) to Dalton's Toronto, Ontario facility. Tue, 25 May 2004 00:00:00 GMT http://www.dalton.com/news_article/25.aspx While the SARS virus raced through nearly 30 countries following its discovery in February, the pursuit by medical researchers to profit from studying the illness likely will be both sluggish and expensive. Sat, 03 May 2003 00:00:00 GMT http://www.dalton.com/news_article/26.aspx Dalton Chemical Laboratories Inc. has become heavily dependent on workers from other countries in recent years. Thu, 01 May 2003 00:00:00 GMT http://www.dalton.com/news_article/24.aspx When Malcolm Oliver moved his family to Canada from Bombay last fall, he knew landing work would be tough. But he didn't count on finding a culturally diverse workplace full of other newcomers also struggling to adjust to new jobs and lives. Mon, 17 Mar 2003 00:00:00 GMT http://www.dalton.com/news_article/27.aspx By all accounts, the Triad -- particularly a trio of pharmaceutical firms and the Piedmont Triad Research Park in Winston-Salem -- succeeded in getting noticed at the world's largest annual biotechnology conference in Toronto last week. Sun, 30 Jun 2002 00:00:00 GMT http://www.dalton.com/news_article/28.aspx A lack of specialized expertise, tight time frames and the need for optimal resource utilization is leading more research departments to seek out outsourcing solutions to everything from drug discovery to manufacturing. Thu, 20 Jun 2002 00:00:00 GMT http://www.dalton.com/news_article/29.aspx VirulizinÒ is a potent and unique immunotherapy that directly stimulates macrophages and enhances their ability to kill tumor cells. VirulizinÒ is being studied as a first line therapy in combination with gemcitabine for the treatment of pancreatic cancer. Tue, 04 Jun 2002 00:00:00 GMT http://www.dalton.com/news_article/31.aspx Dalton in the final stages of an expansion project and move of its operations from York University, to a 42,000 sq.ft. facility across the street in Toronto, ON. Fri, 12 Apr 2002 00:00:00 GMT http://www.dalton.com/news_article/30.aspx Dalton Chemical Laboratories Inc. (the Company) is pleased to announce that it has signed an agreement with Lorus Therapeutics to manufacture its lead anti-cancer drug Virulizin®. Mon, 12 Mar 2001 00:00:00 GMT http://www.dalton.com/news_article/32.aspx Dalton Chemical Laboratories, a longtime leader in commercial oligo supply in Canada, has expanded its biopolymer operation with the launch of a custom peptide synthesis operation. Thu, 22 Jul 1999 00:00:00 GMT